Skye Bioscience, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Skye Bioscience, Inc. (SKYE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-10
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $306.76K, a 27.22% increase from fiscal 2023.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $241.13K.
- Skye Bioscience, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | |||
| 2024-12-31 | $306.76K 10-K · filed 2026-03-10 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $241.13K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $241.13K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $241.13K 10-Q · filed 2023-08-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $0.00 derived: sum of 2 quarters · filed 2024-03-22 | $0.00 10-K · filed 2024-03-22 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |